Westchester Capital Management (New York)’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Westchester Capital Management (New York)’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,100	Closed	-$11K	–	487
2022 Q3	$11K	Hold	1,100	–	–	﹤0.01%	445
2022 Q2	$11K	Hold	1,100	–	–	﹤0.01%	411
2022 Q1	$11K	Hold	1,100	–	–	﹤0.01%	413
2021 Q4	$11K	Hold	1,100	–	–	﹤0.01%	386
2021 Q3	$11K	Buy	+1,100	New	+$10.7K	﹤0.01%	359

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Westchester Capital Management (New York)'s EUCR Position: Q4 2022 in Review

Westchester Capital Management (New York) sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 1,100 shares — an estimated $11K sold.

Westchester Capital Management (New York) first reported a position in EUCR in Q3 2021 and held it in 5 quarters. The position peaked at $11K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Westchester Capital Management (New York) reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Westchester Capital Management (New York) sold 1,100 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $11K.
Westchester Capital Management (New York) first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 5 quarters.
Westchester Capital Management (New York)'s Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $11K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.